Pvr-KO tumors grew slightly slower than wild-type tumors, and combination with anti-PD-1 and anti-CTLA-4 mAbs inhibited pvr-KO tumor growth (figure 5B and online supplemental figure S4E). Here, CTLA4 is linked to neoplasm.